+86-27-65522453 sales@sun-shinechem.com


Catalog No.: 16071022
Cas No.: 366017-09-6
Purity : 98% by HPLC 
16071022 - Mubritinib | CAS 366017-09-6

Catalog number : 16071022

CAS number : 366017-09-6

Molecular Formula : C25H23F3N4O2 

Molecular Weight : 468.47093 

Iupac Chemical Name : (E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole 

Smile : N1(N=NC=C1)CCCCC1=CC=C(OCC=2N=C(OC2)\C=C\C2=CC=C(C=C2)C(F)(F)F)C=C1


PackagingPriceAvailabilityPurityEstimated Shipping Time
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
SynonymsMubritinib; TAK 165 
Molecular FormulaC25H23F3N4O2 
Molecular Weight468.47093 
AppearanceSolid powder 
Purity98% by HPLC 
SolubilitySoluble in DMSO 
Storage-20 ºC for 3 years 
Shipping ConditionShipped under ambient temperature 
Coming soon.
Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials (may be discontinued since 2008). Mubritinib(TAK 165) is a potent EGFR, HER2 and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 ÂM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5. Mubritinib(TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Mubritinib(TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo. 

366017-09-6 - Request Bulk Quote

366017-09-6 - Request Bulk Quote